Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

1.003 -0.017 (-1.67%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Enlivex Therapeutics Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
Which stocks have an unusual volume on Tuesday?
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
Dow Dips 100 Points; CarMax Earnings Miss Views
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday. 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94.... 
Via Benzinga
Topics Stocks
Exposures US Equities
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
ENLV stock results show that Enlivex Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
This month, H.C. Wainwright & Co. 
Via Benzinga
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
This month, Enlivex Therapeutics Ltd. 
Via Benzinga
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Gainers PLx Pharma Inc. (NASDAQ: PLXP) jumped 149.6% to $0.2623 in pre-market trading after dropping over 13% on Thursday. 
Via Benzinga
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
By Rachael Green, Benzinga 
Via News Direct
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
By Rachael Green, Benzinga 
Via News Direct
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
By Rachael Green, Benzinga 
Via News Direct
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an  Investigational New Drug (IND) application to study Allocetra™ in patients with... 
Via Benzinga
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose 
Via Benzinga
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment
Enlivex Therapeutics Ltd. 
Via Benzinga
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
Sign up for this week’s All Access giveaway here! 
Via Benzinga
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera 
Via Benzinga
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and... 
Via Benzinga
Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That
One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms. 
Via Benzinga
Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders
Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 
Via Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.